All News

Oldest and most frail elderly were at more than 60% greater risk of bleeding when switched from a VKA than those who remained on the traditional agent.

Findings from a recent study show a broad spectrum of possible clinical manifestations of IRD following SARS-CoV-2 infection or COVID-19 vaccination.

ESC Congress 2023. The results of STEP-HFpEF could "change the nature of the conversation about the role of obesity in HFpEF," said PI Mikhail Kosiborod, MD.

The expanded labeling for the antiviral against COVID-19 indicates no dose adjustment is required for persons across all stages of liver disease.

The first biosimilar to the approved formulation of natalizumab is indicated for relapsing forms of MS and for induction/maintenance of remission in adults with Crohn disease.

A large study of hospitalized children with SARS-CoV-2 infection found that disease severity varied by age over the course of the COVID-19 pandemic.

Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.

A daily dose of clinical news on Patient Care you may have missed.

In an analysis of participant data from health surveys, less than half of eligible persons in the overall pooled sample were taking aspirin for secondary prevention of CVD.

A daily dose of clinical news on Patient Care you may have missed.

Before creating a nutrition plan for patients with obesity, clinicians should first understand their eating patterns, says one obesity expert.

The most common nonfatal injuries are caused by unintentional falls; coming in at #10 are pedal cyclist injuries. Find out what calamities lie in between in a short slide show.

The FDA approved Abrysvo for use in pregnant individuals to prevent LRTD and severe LRTD caused by RSV in infants from birth through 6 months of age.

Well-known ID specialist Bill Schaffner, MD, and active primary care educator Chuck Vega, MD, offer thoughts on how to get shots into arms in the 2023-2024 respiratory virus season.

A daily dose of clinical news on Patient Care you may have missed.

More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.

The newly named centers across the country will work closely with communities to focus research on populations at greatest risk for perinatal morbidity and mortality.

Patients hospitalized with COVID-19 were 2-times more likely to develop persistent hypertension than their influenza counterparts, according to results.